<DOC>
	<DOCNO>NCT02472756</DOCNO>
	<brief_summary>This Phase 4 , open , prospective , non-interventional , multicenter trial previously treat adult participant relapsed/refractory follicular lymphoma ( FL ) . Eligible participant FL receive 6-8 infusion induction standard regimen rituximab plus chemotherapy . Participants complete partial remission end induction assign maintenance therapy rituximab every 3 month maximum 2 year relapse . The choice treatment regimen establish per center basis , accord standard use country center , center use regimen study . Participants follow safety efficacy evaluation accordance routine practice .</brief_summary>
	<brief_title>A Study Rituximab Combination With Chemotherapy Relapsed/Refractory Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Participants diagnose FL already receive one treatment Participants eligible rituximab treatment accord summary product characteristic ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>